Replay 2024-12 Las Vegas

At the completion of this activity, the participant will be able to:

1. Discuss the mechanisms of action, role and pros/cons of SGLT2-inhibitors and finerenone in the prevention of CKD progression.  

2. Discuss the mechanisms of action, pharmacokinetic, and pharmacodynamic characteristics of loop and thiazide diuretic agents.  

3. Describe the mechanisms of action and pros/cons of therapies for the management of hyperkalemia, anemia, and CKD-MBD.  

4. Choose an appropriate management for edema, acute and chronic hyperkalemia, anemia, and CKD-MDB in a patient with CKD.  

5. Discuss the mechanisms of action, role and pros/cons of current and emerging therapies for the treatment of IgA Nephropathy. 

At the conclusion of this program, the participant will be able to:

1. Discuss the burden of opioid misuse and abuse on the individual and society.

2. Describe the funda- mental concepts of pain management, including: a) addiction; b) tolerance; c) dependency; d) hyperalgesia; e) allodynia.

3. State key principles for assessing patients in pain, identifying risk factors and behaviors that are associated with opioid misuse, abuse, and addiction.

4. Describe the similarities and differences in the mechanism of action for opioids, cannabinoids and gabapentenoids.

5. Compare and contrast the benefits, risks and role of opioids, cannabinoids and gabapentenoids in managing pain.

6. Describe the best practice model for properly monitoring patients who are started on opioids, gabapentenoids and cannabinoids to minimize the risks of adverse reactions, over-dosage and inappropriate compliance.

7. Compare and contrast the following product formulations of gabapentenoids with respect to their benefits and risks in managing pain: a) gabapentin (Neurontin); b) Horizant; c) Gralise; and, d) Lyrica.

8. Compare and contrast the most common cannabinoids found in marijuana with regards to their benefits and risks in managing pain and other symptoms.

9. State the risks of combining opioids with: a) benzodiazepines; b) alcohol; c) gabapentenoids; and d) cannabinoids.

10. Describe how to counsel patients and caregivers regarding the safe use on naloxone for opioid overdose  

At the conclusion of this program, the participant will be able to:

Protecting the Vulnerable: Improving Safety of Antimicrobials in the Elderly Population:  

1. Evaluate methods to improve safety of antimicrobial prescribing in the elderly.  

2. Review antimicrobial therapy recommendations within Beers Criteria.  

3. Examine best antimicrobials practices through case application.   

Mastering Migraine Management: Update on Current Therapies:  

4. Review current older management strategies for migraine headaches.  

5. Discuss role of newer agents including CGRP inhibitors.  

6. Examine best practices through case application.  

Obesity and Weight Loss:  

7. Review risk factors and criteria within obesity  

8. Describe appropriate patient populations for weight loss pharmacotherapy.  

9. Delineate key characteristics of various approved and future pharmacotherapy options including GLP-1 and GIP agonists.  

10. Apply knowledge within patient cases to select an appropriate pharmacotherapy option.